These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 27259007)

  • 1. ETV6-NTRK3 Is Expressed in a Subset of ALK-Negative Inflammatory Myofibroblastic Tumors.
    Alassiri AH; Ali RH; Shen Y; Lum A; Strahlendorf C; Deyell R; Rassekh R; Sorensen PH; Laskin J; Marra M; Yip S; Lee CH; Ng TL
    Am J Surg Pathol; 2016 Aug; 40(8):1051-61. PubMed ID: 27259007
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ALK, ROS1 and NTRK3 gene rearrangements in inflammatory myofibroblastic tumours.
    Yamamoto H; Yoshida A; Taguchi K; Kohashi K; Hatanaka Y; Yamashita A; Mori D; Oda Y
    Histopathology; 2016 Jul; 69(1):72-83. PubMed ID: 26647767
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anaplastic lymphoma kinase-negative uterine inflammatory myofibroblastic tumor containing the ETV6-NTRK3 fusion gene: a case report.
    Takahashi A; Kurosawa M; Uemura M; Kitazawa J; Hayashi Y
    J Int Med Res; 2018 Aug; 46(8):3498-3503. PubMed ID: 29900760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mammary Analogue Secretory Carcinoma of Salivary Glands: Molecular Analysis of 25 ETV6 Gene Rearranged Tumors With Lack of Detection of Classical ETV6-NTRK3 Fusion Transcript by Standard RT-PCR: Report of 4 Cases Harboring ETV6-X Gene Fusion.
    Skálová A; Vanecek T; Simpson RH; Laco J; Majewska H; Baneckova M; Steiner P; Michal M
    Am J Surg Pathol; 2016 Jan; 40(1):3-13. PubMed ID: 26492182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pan-tropomyosin receptor kinase immunoreactivity, ETV6-NTRK3 fusion subtypes, and RET rearrangement in salivary secretory carcinoma.
    Yamamoto H; Nozaki Y; Sugii A; Taguchi K; Hongo T; Jiromaru R; Sato M; Nakano T; Hashimoto K; Fujiwara M; Oda Y
    Hum Pathol; 2021 Mar; 109():37-44. PubMed ID: 33301751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expanding the Molecular Characterization of Thoracic Inflammatory Myofibroblastic Tumors beyond ALK Gene Rearrangements.
    Chang JC; Zhang L; Drilon AE; Chi P; Alaggio R; Borsu L; Benayed R; Travis WD; Ladanyi M; Antonescu CR
    J Thorac Oncol; 2019 May; 14(5):825-834. PubMed ID: 30550870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Salivary Secretory Carcinoma Harboring a Novel ALK Fusion: Expanding the Molecular Characterization of Carcinomas Beyond the ETV6 Gene.
    Sasaki E; Masago K; Fujita S; Suzuki H; Hanai N; Hosoda W
    Am J Surg Pathol; 2020 Jul; 44(7):962-969. PubMed ID: 32205481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary inflammatory myofibroblastic tumour of the liver: a clinicopathological and genetic study including a subset with ETV6::NTRK3 fusion.
    Han Q; Zhang Z; He X; Chen M; Pang X; Chen C; Du T; Zhang H
    Histopathology; 2023 May; 82(6):925-936. PubMed ID: 36748182
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of ROS1 predicts ROS1 gene rearrangement in inflammatory myofibroblastic tumors.
    Hornick JL; Sholl LM; Dal Cin P; Childress MA; Lovly CM
    Mod Pathol; 2015 May; 28(5):732-9. PubMed ID: 25612511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pan-TRK Immunohistochemistry Is Highly Correlated With NTRK3 Gene Rearrangements in Salivary Gland Tumors.
    Csanyi-Bastien M; Lanic MD; Beaussire L; Ferric S; François A; Meseure D; Jardin F; Wassef M; Ruminy P; Laé M
    Am J Surg Pathol; 2021 Nov; 45(11):1487-1498. PubMed ID: 33899788
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Secretory Breast Carcinoma: A Histopathologic and Genomic Spectrum Characterized by a Joint Specific ETV6-NTRK3 Gene Fusion.
    Del Castillo M; Chibon F; Arnould L; Croce S; Ribeiro A; Perot G; Hostein I; Geha S; Bozon C; Garnier A; Lae M; Vincent-Salomon A; MacGrogan G
    Am J Surg Pathol; 2015 Nov; 39(11):1458-67. PubMed ID: 26291510
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expanding the Molecular Spectrum of Secretory Carcinoma of Salivary Glands With a Novel VIM-RET Fusion.
    Skálová A; Banečkova M; Thompson LDR; Ptáková N; Stevens TM; Brcic L; Hyrcza M; Michal M; Simpson RHW; Santana T; Michal M; Vaněček T; Leivo I
    Am J Surg Pathol; 2020 Oct; 44(10):1295-1307. PubMed ID: 32675658
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic utility of pan-Trk immunohistochemistry for inflammatory myofibroblastic tumours.
    Yamamoto H; Nozaki Y; Kohashi K; Kinoshita I; Oda Y
    Histopathology; 2020 Apr; 76(5):774-778. PubMed ID: 31578734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular characterization of inflammatory myofibroblastic tumors with frequent ALK and ROS1 gene fusions and rare novel RET rearrangement.
    Antonescu CR; Suurmeijer AJ; Zhang L; Sung YS; Jungbluth AA; Travis WD; Al-Ahmadie H; Fletcher CD; Alaggio R
    Am J Surg Pathol; 2015 Jul; 39(7):957-67. PubMed ID: 25723109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nanostring-based screening for tyrosine kinase fusions in inflammatory myofibroblastic tumors.
    Kurihara T; Suehara Y; Akaike K; Hayashi T; Kohsaka S; Ueno T; Hasegawa N; Takagi T; Sasa K; Okubo T; Kim Y; Mano H; Yao T; Kaneko K; Saito T
    Sci Rep; 2020 Oct; 10(1):18724. PubMed ID: 33127954
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene rearrangements in consecutive series of pediatric inflammatory myofibroblastic tumors.
    Preobrazhenskaya EV; Iyevleva AG; Suleymanova AM; Tiurin VI; Mitiushkina NV; Bizin IV; Ivanstov AO; Gorustovich OA; Shelekhova KV; Kachanov DY; Varfolomeeva SR; Roschin VY; Kazakova AN; Litvinov DV; Shamanskaya TV; Savelov NA; Suspitsin EN; Imyanitov EN
    Pediatr Blood Cancer; 2020 May; 67(5):e28220. PubMed ID: 32064735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular Profiling of Salivary Gland Intraductal Carcinoma Revealed a Subset of Tumors Harboring NCOA4-RET and Novel TRIM27-RET Fusions: A Report of 17 cases.
    Skálová A; Vanecek T; Uro-Coste E; Bishop JA; Weinreb I; Thompson LDR; de Sanctis S; Schiavo-Lena M; Laco J; Badoual C; Santana Conceiçao T; Ptáková N; Baněčkova M; Miesbauerová M; Michal M
    Am J Surg Pathol; 2018 Nov; 42(11):1445-1455. PubMed ID: 30045065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of ALK rearrangement by immunohistochemistry in lung adenocarcinoma and the identification of a novel EML4-ALK variant.
    To KF; Tong JH; Yeung KS; Lung RW; Law PP; Chau SL; Kang W; Tong CY; Chow C; Chan AW; Leung LK; Mok TS
    J Thorac Oncol; 2013 Jul; 8(7):883-91. PubMed ID: 23625156
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A sensitive and high throughput TaqMan-based reverse transcription quantitative polymerase chain reaction assay efficiently discriminates ALK rearrangement from overexpression for lung cancer FFPE specimens.
    Lung J; Lin YC; Hung MS; Jiang YY; Lee KD; Lin PY; Tsai YH
    Lung Cancer; 2016 Apr; 94():114-20. PubMed ID: 26973216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of an ETV6-NTRK3 rearrangement with unusual, but highly significant FISH signal pattern in a secretory carcinoma of the salivary gland: a case report.
    Wagner F; Greim R; Krebs K; Luebben F; Dimmler A
    Diagn Pathol; 2021 Aug; 16(1):73. PubMed ID: 34372873
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.